SC
VINC

Steven Cohen’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Steven Cohen’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-33,710
Closed -$483K – 2560
2024
Q3 		$483K Hold
33,710
– – ﹤0.01% 1617
2024
Q2 		$546K Sell
33,710
-14,031
-29% -$352K ﹤0.01% 1424
2024
Q1 		$4.83M Buy
47,741
+30,500
+177% +$1.93M 0.01% 973
2023
Q4 		$407K Hold
17,241
– – ﹤0.01% 1634
2023
Q3 		$348K Hold
17,241
– – ﹤0.01% 1619
2023
Q2 		$448K Sell
17,241
-25
-0.1% -$715 ﹤0.01% 1286
2023
Q1 		$359K Buy
17,266
+25
+0.1% +$560 ﹤0.01% 1318
2022
Q4 		$352K Hold
17,241
– – ﹤0.01% 1191
2022
Q3 		$476K Hold
17,241
– – ﹤0.01% 1175
2022
Q2 		$455K Hold
17,241
– – ﹤0.01% 1204
2022
Q1 		$1.38M Hold
17,241
– – 0.01% 927
2021
Q4 		$3.51M Hold
17,241
– – 0.01% 743
2021
Q3 		$5.14M Buy
+17,241
New +$5.03M 0.02% 656

Other funds holding VINC

SRC
Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Steven Cohen's VINC Position: Q4 2024 in Review

Steven Cohen sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q4 2024, closing a stake of 33,710 shares — an estimated $483K sold.

Steven Cohen first reported a position in VINC in Q3 2021 and held it in 13 quarters. The position peaked at $5.14M in Q3 2021. 22 funds tracked by Wall St. Rank hold VINC as of Q4 2024.

  • Steven Cohen reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Steven Cohen sold 33,710 Vincerx Pharma, Inc. Common Stock shares in Q4 2024, an estimated $483K.
  • Steven Cohen first reported a position in Vincerx Pharma, Inc. Common Stock in Q3 2021 and held it in 13 quarters.
  • Steven Cohen's Vincerx Pharma, Inc. Common Stock position peaked at $5.14M in Q3 2021.
  • 22 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q4 2024.

Based on Point72 Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.